Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant releases one-year DES data

This article was originally published in The Gray Sheet

Executive Summary

Angiographic in-stent late loss and in-segment late loss with Guidant's Xience V everolimus-eluting stent are 72% and 78% lower than with Guidant's bare metal Multi-Link Vision, according to 12-month results from the firm's SPIRIT FIRST feasibility trial. Xience V showed a device-related major adverse cardiac event rate of 3.8% (1/26) compared with 21.4% (6/28) in the control arm. Xience V is also being measured against Boston Scientific's Taxus paclitaxel-eluting stent in two ongoing European trials (1"The Gray Sheet" Sept. 26, 2005, In Brief)...

You may also be interested in...



Guidant’s SPIRIT

Over 300 patients are enrolled in the SPIRIT II and SPIRIT III European drug-eluting stent clinical trials, triggering a $60 mil. milestone payment to drug-supplier Novartis, Guidant announces Sept. 21. The trial compares Guidant's Xience V everolimus-eluting stent to Boston Scientific's Taxus paclitaxel-eluting stent. In June, FDA approved an expansion of the SPIRIT III trial to include 1,292 patients at up to 80 sites (1"The Gray Sheet" Aug. 29, 2005, In Brief). The notified body that will review Xience for CE Mark completed its inspection of the firm's Temecula, Calif. facility...

Guido Rasi - The Face Of The EMA For A Decade

The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.

 

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.
UsernamePublicRestriction

Register

MT022917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel